We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

117 hedge funds and large institutions have $396M invested in Vanda Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 36 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $4.24M | Put options by funds: $2.26M

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

8% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 36

4% less funds holding

Funds holding: 122 → 117 (-5)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

18% less capital invested

Capital invested by funds: $481M → $396M (-$85.1M)

Holders
117
Holders Change
-5
Holders Change %
-4.1%
% of All Funds
3.07%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.13%
New
21
Increased
33
Reduced
36
Closed
25
Calls
$4.24M
Puts
$2.26M
Net Calls
+$1.98M
Net Calls Change
-$6.59M

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$12.1M
2
AC
Armistice Capital
New York
+$8.68M
3
JGC
J. Goldman & Co
New York
+$4.2M
4
GPP
Great Point Partners
Connecticut
+$3.84M
5
Renaissance Technologies
Renaissance Technologies
New York
+$3.37M

Top Sellers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
-$11.3M
2
KCM
Kingdon Capital Management
New York
-$10.1M
3
ACA
Avoro Capital Advisors
New York
-$8.62M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$8.46M
5
State Street
State Street
Massachusetts
-$7.98M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$2.94M -$6.22M -623,745 -66%
Charles Schwab
27
Charles Schwab
California
$2.5M +$1.94M +194,080 +260%
AC
28
Ascend Capital
California
$2.32M +$2.49M +249,596 New
Principal Financial Group
29
Principal Financial Group
Iowa
$1.94M – – –
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.75M -$194K -19,408 -9%
PP
31
PDT Partners
New York
$1.63M -$1.05M -105,155 -38%
BIM
32
BlackRock Investment Management
Delaware
$1.41M +$7.42K +743 +0.5%
Fidelity Investments
33
Fidelity Investments
Massachusetts
$1.4M +$1.5M +150,078 New
UBS Group
34
UBS Group
Switzerland
$1.29M +$1.09M +109,346 +377%
TCIM
35
TIAA CREF Investment Management
New York
$1.25M – – –
CCM
36
Convector Capital Management
New York
$1.2M +$1.28M +128,500 New
Citadel Advisors
37
Citadel Advisors
Florida
$1.02M -$245K -24,585 -18%
Credit Agricole
38
Credit Agricole
France
$938K – – –
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$872K +$845K +84,659 +935%
Thrivent Financial for Lutherans
40
Thrivent Financial for Lutherans
Minnesota
$866K +$929K +93,060 New
State Board of Administration of Florida Retirement System
41
State Board of Administration of Florida Retirement System
Florida
$827K -$366K -36,654 -29%
Connor, Clark & Lunn Investment Management (CC&L)
42
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$782K -$58.9K -5,900 -7%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$721K +$13.7K +1,375 +2%
TC
44
TFS Capital
Pennsylvania
$720K -$445K -44,592 -37%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$686K – – –
PA
46
Perceptive Advisors
New York
$669K +$717K +71,849 New
VEA
47
Virtus ETF Advisers
New York
$624K +$669K +67,021 New
RFC
48
Russell Frank Company
Washington
$560K +$578K +57,960 New
TA
49
Teachers Advisors
New York
$555K – – –
Goldman Sachs
50
Goldman Sachs
New York
$552K -$771K -77,268 -57%
1
2
3 4 5

VNDA Hedge Fund Activity: Q4 2015 in Review

117 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2015, worth a combined $396M — down 18% from $481M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of VNDA and 21 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 33 added.

The largest buyer was Deerfield Management, adding an estimated $12.1M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $11.3M sold.

  • 117 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2015, down from 122 in Q3 2015.
  • Funds reported $396M of Vanda Pharmaceuticals stock for Q4 2015, down 18% quarter-over-quarter.
  • 21 funds opened new Vanda Pharmaceuticals positions in Q4 2015 and 25 closed out, a net change of -4 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2015 was Deerfield Management, an estimated $12.1M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2015 was EverPoint Asset Management, an estimated $11.3M sold.

Based on aggregated 13F filings for Q4 2015.